Minoxidil

Catalog NumberHG38304915

CAS Number38304-91-5

CategoryNon-ionic Surfactants

Synonyms

2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide;Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide

Molecular Weight

209.25

Molecular Formula

C9H15N5O

Appearance

Solid

Application

Use as pharmaceutical ingredient.; Use as emulsifying agent, dispersing agent.; Use as antirust agent, corrosion inhibitor.

Active Content

95%

Download COA Download MSDS

Case Study

Minoxidil as a Hair Growth Promoter for Androgenetic Alopecia Treatment

Hussein, Ramadan S., et al. Skin health and disease 4.6 (2024): ski2-472.

Minoxidil functions as a potassium channel opener and hair growth promoter in the management of androgenetic alopecia.
Experimental Protocol: Clinical studies evaluate topical minoxidil at concentrations of 2% and 5% applied twice daily, as well as oral minoxidil at dosages ranging from 0.25 to 5 mg per day. Treatment durations typically span 24 to 48 weeks, with assessments conducted via standardized phototrichogram analysis and hair count measurements. Combination therapy with finasteride or low-level laser therapy is also examined.
Performance Evaluation: Topical 5% minoxidil demonstrates superior efficacy over the 2% formulation, producing a statistically significant increase in total hair count of approximately 18 to 26 hairs per cm² after 48 weeks. Oral minoxidil at low doses (0.25 to 2.5 mg daily) shows comparable efficacy with improved patient compliance. Hypertrichosis occurs in 3 to 15% of patients depending on dosage. The treatment exhibits a responder rate of approximately 60 to 70% across all formulations.

Minoxidil as an Oral Therapeutic Agent for Hair Loss Management

Randolph, Michael, et al. Journal of the American Academy of Dermatology 84.3 (2021): 737-746.

Oral minoxidil serves as a systemic therapeutic agent for the management of various hair loss conditions including androgenetic alopecia, telogen effluvium, and chronic telogen effluvium.
Experimental Protocol: Patients receive oral minoxidil at dosages of 0.25 to 5 mg once daily, with treatment periods ranging from 6 to 24 months. Efficacy is evaluated using standardized global photography, trichoscopy, and patient-reported outcome measures. Safety monitoring includes assessment of hypertrichosis, pedal edema, and cardiovascular parameters.
Performance Evaluation: Oral minoxidil at 0.25 to 2.5 mg daily produces significant hair count increases of 12 to 22 hairs per cm² in androgenetic alopecia patients after 12 months. The treatment achieves a 70 to 85% satisfaction rate among patients. Hypertrichosis occurs in 50 to 80% of patients at higher doses (2.5 to 5 mg) but is generally mild and reversible. No serious cardiovascular adverse events are reported at low doses. The therapy demonstrates particular efficacy for female pattern hair loss with a 60 to 75% response rate.

• Synonyms: 2,4-Pyrimidinediamine, 6-(1-piperidinyl)-, 3-oxide;Pyrimidine, 2,4-diamino-6-piperidino-, 3-oxide
• Molecular Weight: 209.25
• Molecular Formula: C9H15N5O
• Appearance: Solid
• Application: Use as pharmaceutical ingredient.; Use as emulsifying agent, dispersing agent.; Use as antirust agent, corrosion inhibitor.
• Active Content: 95%